# Substance Use & Co-Occurring Disorders

> Psychiatry at CRC Substance Use & Co-Occurring Disorders Psychiatric evaluation and treatment at Core Revitalizing Center in Lakewood Ranch, Florida Core Revitalizing Center | Tariq Halim, MD, board-certified psychiatrist. Alcohol, opioids, and other substances can become part of how you…
> URL: https://corerevitalizingcenter.com/substance-use-co-occurring-disorders/
> Last modified: 2026-11-20T20:28:02+00:00

[Psychiatry at CRC](/behavioral-health-services/)

# Substance Use & Co-Occurring Disorders

Psychiatric evaluation and treatment at Core Revitalizing Center in Lakewood Ranch, Florida

Core Revitalizing Center | [Tariq Halim, MD, board-certified psychiatrist](/about/#clinicians-heading).

Alcohol, opioids, and other substances can become part of how you manage pain, anxiety, sleep, or the demands of daily life. You may be concerned about your use, unsure how it relates to your mental health, or finding that earlier attempts to change have not lasted.

I want to understand what the substance is doing for you, what it is costing you, and what will help you move forward safely. That means looking at your psychiatric symptoms, your pattern of use, and the circumstances that influence both.

At a glance

Substance use and psychiatric symptoms can affect each other and need assessment together.

I examine their sequence, withdrawal risk, functioning, and available support.

Care may include medication and recovery supports, with referral to supervised or more intensive treatment when outpatient care cannot provide enough safety or monitoring.

On this page 12 sections

[Psychiatric care and substance use belong in the same assessment](#psychiatric-assessment)

[Understanding the pattern of use](#pattern-of-use)

[Treatment addresses both the substance and the reasons for using it](#treatment)

[How the substance shapes treatment](#substance-specific-care)

[Support and the right setting for care](#support-and-setting)

[What we follow over time](#following-progress)

[What makes care here different](#care-here)

[Common questions](#common-questions)

[When to seek urgent help](#urgent-help)

[Related CRC resources](#related-resources)

[Considering an evaluation?](#taking-the-next-step)

[Clinical references](#clinical-references)

## Psychiatric care and substance use belong in the same assessment

Anxiety, depression, disrupted sleep, suspiciousness, and difficulty concentrating can occur before substance use, during use, or during withdrawal. Co-occurring disorders means that a substance use disorder and another psychiatric condition are present together. Both need attention in the treatment plan. [[1](#reference-1)]

I look at the sequence: what was present before the substance became part of your life, what changed as use increased, and what improves or remains when use decreases. That history helps distinguish substance effects from a psychiatric condition that needs its own treatment.

For mood symptoms, I consider the pattern of episodes, changes in sleep and energy, and previous treatment response. For anxiety or trauma-related symptoms, I examine when distress occurs, what brings it on, and how avoidance or substance use has become part of coping. Attention problems require a longer view of development and functioning, because poor sleep, intoxication, and withdrawal can also affect concentration.

When suspiciousness or other psychotic symptoms are present, I assess the timing, severity, and effect on functioning and safety. I revisit the formulation as more information becomes available. A substance history does not answer every psychiatric question, and stopping a substance does not necessarily resolve an underlying condition. [[1](#reference-1)]

Autistic and ADHD adults may use alcohol or other substances to manage sensory overload, social exhaustion, or restlessness. I ask about that function directly, because a plan that removes the substance without addressing what it was doing for you is less likely to last.

## Understanding the pattern of use

I ask what you use, how often, what happens when you reduce it, and how it affects your health, relationships, responsibilities, and decisions. The history includes prescribed medications, nonprescribed substances, supplements, and products sold as natural. Previous treatment and periods of stability help identify what has worked and where the difficulties remain.

Physical dependence means the body has adapted and may develop withdrawal when a substance is reduced or stopped. It can occur during prescribed treatment. Dependence alone does not establish a substance use disorder; I also assess control over use, cravings, unsuccessful attempts to cut back, and the consequences of continuing.

## Treatment addresses both the substance and the reasons for using it

The plan may include medication for a substance use disorder, treatment of a co-occurring psychiatric condition, practical changes, and counseling or other recovery supports. The priorities depend on safety, symptoms, previous response, and what you can realistically sustain. [[1](#reference-1)]

### Two linked tracks in one plan

#### Substance use

Withdrawal safety

↔

#### Psychiatric condition

Assessment over time

↓

#### Substance use

Medication for the use disorder

↔

#### Psychiatric condition

Treatment of the psychiatric condition

↓

#### Substance use

Relapse prevention

↔

#### Psychiatric condition

Ongoing review

One plan and one physician for both, adjusted as each one changes

Substance use and a co-occurring psychiatric condition are treated as two linked tracks, from safety and assessment through treatment to ongoing review, within one plan and with one physician.This is an illustration to guide discussion, not a diagnostic test.

Read the original diagram description
Substance use and a co-occurring psychiatric condition are treated as two linked tracks in one plan

Two parallel tracks. The substance use track runs from withdrawal safety, to medication for the use disorder, to relapse prevention. The psychiatric condition track runs from assessment over time, to treatment of the psychiatric condition, to ongoing review. Each step on one track is linked to the matching step on the other. A strip below reads: one plan and one physician for both, adjusted as each one changes.

During visits, I help you examine the pattern around use: when it happens, what relief you expect, what follows, and what makes returning to use more likely. Pain, exhausting work schedules, isolation, relationship strain, and disrupted sleep may all need attention. Those details help turn an intention to change into a more workable plan.

Medication decisions include meaningful benefit, side effects, interactions, and the risks of changing treatment. I continue reassessing psychiatric symptoms as substance use changes. Progress in one area does not make the other irrelevant.

## How the substance shapes treatment

### Alcohol

I am conservative about alcohol withdrawal because it can cause seizures and delirium tremens. Outpatient management requires mild to moderate symptoms, low overall risk, reliable support, and frequent clinical monitoring, generally daily early in withdrawal. A history of complicated withdrawal, significant medical comorbidity, or inability to arrange that monitoring leads me to recommend medically supervised withdrawal first. [[2](#reference-2)]

Longer-term care addresses the pattern of drinking and the risk of returning to harmful use. Naltrexone is one option I discuss, including whether a targeted approach sometimes called the Sinclair Method is practical for the individual. It can reduce alcohol’s rewarding effects and cravings. It does not treat acute withdrawal, and opioid exposure must be reviewed before it is considered. [[3](#reference-3), [4](#reference-4)]

### Benzodiazepines

Physical dependence can develop during prescribed benzodiazepine treatment. I use an individualized, gradual taper when reduction is appropriate, sometimes with a longer-acting medication. The pace follows symptoms and stability. High doses, previous withdrawal seizures, difficulty following the plan, or dependence on additional substances may require more supervision. Abrupt discontinuation can be dangerous. [[5](#reference-5)]

### Opioids

For opioid use disorder, my usual outpatient approach is buprenorphine when clinically appropriate, with ongoing attention to cravings, safety, functioning, and treatment continuity. Completing withdrawal alone leaves a substantial risk of returning to use and overdosing after tolerance falls. Medical complications, repeated difficulty starting treatment, fentanyl exposure, or sedative dependence may require a setting with more support. Naloxone and an overdose-response plan are important considerations. [[6](#reference-6), [7](#reference-7), [8](#reference-8)]

The [Opioid Use Disorder Treatment with Buprenorphine page](/buprenorphine-treatment/) explains assessment, medication, and ongoing care in more detail.

### Kratom and concentrated 7-OH products

Kratom products vary, and concentrated or enhanced 7-hydroxymitragynine, also called 7-OH, can produce potent opioid effects and serious harm. I assess withdrawal, cravings, control over use, and consequences. I may use buprenorphine for heavier use with substantial dependence or symptom management for less severe presentations. Treatment must fit the assessment; buprenorphine use for kratom-related problems is off-label, with evidence that remains limited. More supervised care is appropriate when complications or unsuccessful outpatient attempts warrant it. [[9](#reference-9), [10](#reference-10)]

## Support and the right setting for care

Reliable support at home is mainly a requirement when I am managing withdrawal. Someone needs to be able to observe changes, help manage medication according to the treatment plan, and help you get to appointments. For ongoing care, including stable buprenorphine treatment, I assess support needs individually. The substance, severity of dependence, medical stability, psychiatric symptoms, and ability to follow the plan shape that decision.

When withdrawal cannot be managed safely at home or outpatient care cannot provide enough monitoring, I recommend beginning in a structured program. The purpose is to establish safety, support, and a workable treatment plan so that a transition into my outpatient care can become appropriate. Before referral, I review insurance coverage and confirm that the program is accessible to you. Outside-program coverage is separate from CRC’s private-pay visits.

I recommend more intensive dual-diagnosis care when psychiatric instability exceeds what outpatient appointments can safely manage, active suicidality requires closer support, or outpatient attempts have repeatedly failed. Immediate danger requires emergency assessment. When opioid use disorder is present, a change in setting or a benzodiazepine taper should preserve access to appropriate opioid treatment. [[5](#reference-5)]

## What we follow over time

I use a harm-reduction approach: reducing immediate risk while working toward a safer, more sustainable pattern. We discuss goals openly and revisit them as circumstances change. Fewer cravings, less harmful use, more stable sleep, improved functioning, and greater ability to meet responsibilities can all matter.

Follow-up includes what is happening between appointments: medication effects, psychiatric symptoms, setbacks, and the support you can use. Counseling, mutual-help groups, and other recovery resources may be helpful. I consider what you can access and what helps you remain engaged. I encourage patients to view recovery through the [eight dimensions of wellness](/eight-dimensions-of-wellness/), including physical health, supportive relationships, housing and environmental stability, financial pressures, meaningful activities, and personal values. These areas can guide realistic goals and referrals, but they do not replace treatment of withdrawal risks, substance use disorders, or co-occurring psychiatric illness.

This work is part of [Psychiatric Care at Core Revitalizing Center](/behavioral-health-services/), with continued attention to the person and the conditions that need treatment.

## What makes care here different

Every psychiatric evaluation and follow-up at Core Revitalizing Center is with me, Tariq Halim, MD. I consider your history, usual functioning, prior treatment response, medical context, and goals when deciding what needs treatment and how to evaluate progress.

Read more about [Personalized Psychiatric Care](/personalized-care/), [The Highest Level of Psychiatric Care](/highest-level-of-care/), and [Confidentiality](/confidentiality/).

## Common questions about substance use and co-occurring disorders

### Do I have to stop using completely before I can be seen?

No. I use a harm-reduction approach: reducing immediate risk while working toward a safer, more sustainable pattern. Abstinence can be a goal, but it is not a condition for starting care. What I do need is an honest account of what you use, so the plan can be safe.

### Do you prescribe buprenorphine?

Yes. For opioid use disorder, buprenorphine is my usual outpatient approach when it is clinically appropriate, with attention to cravings, safety, functioning, and continuity. [[6](#reference-6)] Naloxone and an overdose-response plan are part of that care. [[8](#reference-8)] The [Opioid Use Disorder Treatment with Buprenorphine page](/buprenorphine-treatment/) has more detail.

### Can I stop drinking or stop a benzodiazepine on my own?

You should not stop either one abruptly without a clinical assessment. Withdrawal from regular alcohol or benzodiazepine use can cause seizures and other serious complications. [[2](#reference-2), [5](#reference-5)] I assess the risk first and plan withdrawal in the safest setting; when outpatient monitoring is not enough, I recommend starting in a supervised program.

### Will information about my substance use be shared?

CRC does not submit a medical insurance claim for a private-pay office visit. That does not remove the privacy rules governing health information. Disclosures may be permitted or required for treatment, safety, and other purposes under applicable law, and some substance use treatment records have additional protections. Prescription information may reach pharmacies and pharmacy benefit plans, while dispensing of controlled substances is reported to Florida’s prescription drug monitoring program when required. The [Confidentiality page](/confidentiality/) explains what remains private and what does not.

## When to seek urgent help

Do not abruptly stop regular alcohol or benzodiazepine use without a clinical assessment. A seizure, severe confusion, hallucinations during withdrawal, loss of consciousness, or slow or absent breathing requires emergency care. Call 911 for a suspected overdose or another immediate medical emergency. If an opioid overdose is suspected and naloxone is available, administer it according to its instructions while emergency help is being obtained. [[2](#reference-2), [5](#reference-5), [8](#reference-8)]

## Related CRC resources

[Opioid Use Disorder Treatment with Buprenorphine](/buprenorphine-treatment/)

[Trauma & Stress-Related Disorders](/trauma-stress-disorders/)

[Mood Disorders](/mood-disorders/)

## Considering an evaluation?

An appointment can help clarify how substance use and psychiatric symptoms interact and whether this practice is the right setting for your care. Core Revitalizing Center provides private-pay outpatient psychiatric care. Review [Billing](/billing/) for payment information and contact the office if you need to clarify fit or timing. A routine appointment request is not an emergency response.

[Review appointment options](/scheduling/)

## Clinical references

1. [Substance Abuse and Mental Health Services Administration. Screening and Treatment of Co-Occurring Disorders.](https://www.samhsa.gov/mental-health/serious-mental-illness/co-occurring-disorders)

2. [American Society of Addiction Medicine. Clinical Practice Guideline on Alcohol Withdrawal Management.](https://www.asam.org/quality-care/clinical-guidelines/alcohol-withdrawal-management-guideline)

3. [National Institute on Alcohol Abuse and Alcoholism. Recommend Evidence-Based Treatment: Know the Options.](https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/recommend-evidence-based-treatment-know-options)

4. [DailyMed. Naltrexone hydrochloride tablet labeling.](https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=390bff41-7bab-b72a-e063-6294a90ad35d)

5. [American Society of Addiction Medicine and partner societies. Joint Clinical Practice Guideline on Benzodiazepine Tapering. 2025.](https://www.asam.org/quality-care/clinical-guidelines/benzodiazepine-tapering)

6. [Substance Abuse and Mental Health Services Administration. Buprenorphine Quick Start Guide.](https://www.samhsa.gov/sites/default/files/quick-start-guide.pdf)

7. [Substance Abuse and Mental Health Services Administration. Detoxification and Substance Abuse Treatment, TIP 45. Medical complications of opioid withdrawal.](https://library.samhsa.gov/sites/default/files/sma15-4131.pdf)

8. [Substance Abuse and Mental Health Services Administration. Opioid Overdose Reversal Medications.](https://www.samhsa.gov/substance-use/treatment/overdose-prevention/opioid-overdose-reversal)

9. [Food and Drug Administration. Products Containing 7-OH Can Cause Serious Harm.](https://www.fda.gov/consumers/consumer-updates/products-containing-7-oh-can-cause-serious-harm)

10. [Broyan VR, Brar JK, Allgaier T, Allgaier JT. Long-term buprenorphine treatment for kratom use disorder: A case series. Substance Abuse. 2022;43(1):763-766.](https://pubmed.ncbi.nlm.nih.gov/35112990/)
